The Proportion of Sustained Complete Response to T-PoRA's at 24 and 52 Weeks After Treatment Cessation

This prospective multi-center interventional trial enrolled 49 ITP patients treated with T-PoRA's between September 2017 and February 2020 across 20 centers in France. Patients had either persistent or chronic primary ITP according to the international consensus criteria. After inclusion, the patients were weaned off El Trumbopag and Romi Plostum over 10 weeks. In the intention to treat analysis group, 56.2 percent of patients achieved a sustained response following discontinuation of T- PoRA's at week 24 and 52.1 percent at week 52.